Bright Minds Biosciences Inc. (DRUG)
Bright Minds Biosciences Inc. (DRUG) tracked by StreetAlpha. It last closed at $20.40 on Nov 20, down 1.45% on the day. Over the last 12 months DRUG insiders bought $0 of stock on the open market and sold $9.8M, according to SEC Form 4 filings.
Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on DRUG
Technical AnalysisPrices may be delayed
The stock is 48% below its 20 day and 118% below its 50 day average. It is 237% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the swing low (Nov 17) at $19.86, and the nearest resistance the Pivot at $20.66.
| RSI (14) | 26.77 | Oversold below 30 | Oversold |
| MACD | -7.99 | Above its signal line | Bullish |
| Stochastic | 22.4 | Middle of its range | Neutral |
| ADX (14) | 46.7 | Strong downtrend | |
| Williams %R | -67.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -52.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −11.3% | Change over 10 sessions | Bearish |
| ATR (14) | $3.60 | Typical daily range, 17.6% of price |
| RSI (14) | 23.69 | Oversold below 30 | Oversold |
| MACD | -11.56 | Below its signal line | Bearish |
| Stochastic | 6.8 | Near the bottom of its range | Oversold |
| ADX (14) | 22.4 | Weak trend | |
| Williams %R | -95.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -171.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −67.7% | Change over 10 sessions | Bearish |
| ATR (14) | $10.12 | Typical daily range, 49.6% of price |
What happened before
See how DRUG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DRUG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options FlowPrices may be delayed
90DNo whale options trades in DRUG in the last 90 days.
DRUG Institutional Ownership
Full report →- ●46 buying vs 45 selling
- ▼Shares held by funds -3.4%
- ▲Funds holding +10
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 110 | 100 | +10.0% |
| In funds' top 10 | 1 | 2 | −50.0% |
| Held by funds | – | – | – |
| New / increased | 17 / 29 | 19 / 47 | −30.3% |
| Reduced / sold out | 37 / 8 | 17 / 12 | +55.2% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
DRUG Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 28 | Cormorant Asset Management, LPFormer 10% Owner | Sale | 109,331 | $89.50 | $9.8M |
From SEC Form 4 filings by DRUG's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DRUG is in one of them and how their past DRUG trades turned out.
DRUG News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DRUG in an article yet. Here's the latest on the wider market.


